Gene
AKT2
AKT2 is a gene biomarker in the evidence tier "Cancer actionable (CGI)". This page lists evidence by type: Assay-provider ledger (7), Actionable biomarkers (1), Trial mentions (11), and 7 more evidence types, each linked to its source.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section (log scale)
2 more sections with rows · 2 sections measured, none recorded
Cancer actionable (CGI)
Evidence over time
Share of that year: what fraction of the trials and papers our biomarker dictionary matched in a year mention AKT2. The denominator is documents that mention any gene, not every registered document, so improving the matcher moves both halves and never rewrites history. Gene named in free-text trial records. A mention, not a validated biomarker. Actionable-biomarker and target-disease-association evidence carries no date in our sources, so it is not on this chart. Publication mentions cover only papers cited by a registered clinical trial, not all of PubMed.
Trial mentions: plotted from 1990 to 2026, the years our matched corpus covers. Not plotted: 1 with no date at all.
Publication mentions: plotted from 1990 to 2023, the years our matched corpus covers. Not plotted: 1 at the structurally incomplete recent edge.
The yearly numbers
| Year | Trial mentions | Share of that year | Publication mentions | Share of that year |
|---|---|---|---|---|
| 2026 | 0 of 8,738 | 0.00% | not measured | |
| 2025 | 1 of 8,875 | 0.01% | not measured | |
| 2024 | 0 of 8,597 | 0.00% | not measured | |
| 2023 | 1 of 8,275 | 0.01% | 13 of 11,460 | 0.11% |
| 2022 | 0 of 8,285 | 0.00% | 15 of 13,598 | 0.11% |
| 2021 | 0 of 8,692 | 0.00% | 11 of 15,045 | 0.07% |
| 2020 | 0 of 7,640 | 0.00% | 12 of 14,459 | 0.08% |
| 2019 | 1 of 7,300 | 0.01% | 15 of 12,159 | 0.12% |
| 2018 | 3 of 6,927 | 0.04% | 19 of 11,854 | 0.16% |
| 2017 | 1 of 6,558 | 0.02% | 14 of 11,595 | 0.12% |
Showing 10 of 37 years.
Assay-provider ledger (7)
Shown in this order: most recent publication first.
| Company | Provider class | Validation | Papers | Most recent publication |
|---|---|---|---|---|
| Molecular You | Diagnostic provider | Analytical validation | 1 | February 07, 2025 |
| MRM Proteomics | Reagent supplier | Analytical validation | 1 | February 07, 2025 |
| BIO-RAD | Reagent supplier | Clinical validationAnalytical validation | 1 | November 08, 2019 |
| QIAGEN | Reagent supplier | Clinical validationAnalytical validation | 2 | November 08, 2019 |
| THERMO FISHER SCIENTIFIC (Click-iT EdU kit, TaqMan Low-Density Array reagents, ExpressionSuite/DataAssist software) | Reagent supplier | Clinical validationAnalytical validation | 1 | November 08, 2019 |
Showing 5 of 7 assay-provider companies.
Actionable biomarkers (1)
Shown in this order: fixed catalogue order, not ranked.
| Alteration | Drug | Response | Disease | Source |
|---|---|---|---|---|
| AKT2 amplification | Mk2206 | response-associated | No disease recorded | Cancer Genome Interpreter |
Trial mentions (11)
Shown in this order: fixed catalogue order, not by date.
| Trial | Source |
|---|---|
| NCT04192981 | Trial eligibility (AACT) |
| NCT03317366 | Trial eligibility (AACT) |
| NCT03452774 | Trial eligibility (AACT) |
| NCT02639286 | Trial eligibility (AACT) |
| NCT05554380 | Trial eligibility (AACT) |
Showing 5 of 11 trial mentions.
Target-disease associations (462)
Shown in this order: fixed catalogue order, not ranked.
| Disease | Therapeutic area | Source |
|---|---|---|
| 3-hydroxy-3-methylglutaryl-CoA synthase deficiency | genetic, familial or congenital disease | Mouse knockout (IMPC) |
| 46,XX gonadal dysgenesis | endocrine system disease | Mouse knockout (IMPC) |
| 46,XX ovotesticular disorder of sex development | endocrine system disease | Mouse knockout (IMPC) |
| 46,XX testicular disorder of sex development | endocrine system disease | Mouse knockout (IMPC) |
| 46,XY complete gonadal dysgenesis | cardiovascular disease | Mouse knockout (IMPC) |
Showing 5 of 462 associations.
Vendor sourcing (36)
Shown in this order: alphabetical by organization.
| Organization | Role | Tier | Evidence | Citation |
|---|---|---|---|---|
| Ambry Genetics (United States) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | The c.1117C>G (p.L373V) alteration is located in exon 11 (coding exon 10) of the AKT2 gene. This alteration results from a C to G substitution at nucleotide ... | View ClinVar record SCV003536834.3 |
| ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | Trial sponsor | Named in trial inclusion criteriaTrial eligibility criteria | : 1. Severe overgrowth diseases and/or vascular anomalies with confirmed somatic genetic alterations of PIK3CA or AKT 2. Are unable to participate in an ong... | View trial NCT03317366 |
| ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | Trial sponsor | Mentioned in trial textTrial free-text mention | AKT2 | View trial NCT03317366 |
| Elif Oral | Trial sponsor | Mentioned in trial textTrial free-text mention | AKT2 | View trial NCT03508687 |
| GeneDx Holdings Corp. | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | This variant is associated with the following publications: (PMID: 33768461) | View ClinVar record SCV001828367.1 |
Showing 5 of 36 sourcing records.
Trial-cited literature (202)
Shown in this order: newest first, then most cited.
| Publication | Journal | Year | Citations |
|---|---|---|---|
| TCL1A in naïve B cells as a therapeutic target for type 1 diabetes. | EBioMedicine | 2025 | 7 |
| Genomic-transcriptomic evolution in lung cancer and metastasis. | Nature | 2023 | 173 |
| Current State and Future Challenges for PI3K Inhibitors in Cancer Therapy. | Cancers | 2023 | 89 |
| Regulation of Macronutrients in Insulin Resistance and Glucose Homeostasis during Type 2 Diabetes Mellitus. | Nutrients | 2023 | 65 |
| Influence of Genomic Landscape on Cancer Immunotherapy for Newly Diagnosed Ovarian Cancer: Biomarker Analyses from the IMagyn050 Randomized Clinical Trial. | Clinical cancer research : an official journal of the American Association for Cancer Research | 2023 | 49 |
Showing 5 of 202 papers.
Protein variant mentions (7)
Shown in this order: alphabetical by variant.
| Variant | Distinct papers | Year range | Sample papers |
|---|---|---|---|
| p.D324G | 1 | 2022 | PMID 35440569 |
| p.D94E | 1 | 2015 | PMID 25741868 |
| p.E17K | 1 | 2013 | PMID 23739063 |
| p.G116A | 1 | 2015 | PMID 25741868 |
| p.R15H | 1 | 2015 | PMID 25741868 |
Showing 5 of 7 variants.
Human sample screening reference (2)
Shown in this order: alphabetical by variant.
| Variant | GDC project | Disease / site | Affected cases | Profiled cases | Observed frequency | 95% interval |
|---|---|---|---|---|---|---|
| p.D324G | TCGA-KIRC | Adenomas and Adenocarcinomas; Kidney | 1 | 536 | 0.19% | 0.03% to 1.05% |
| p.D324G | TCGA-LIHC | Adenomas and Adenocarcinomas; Liver and intrahepatic bile ducts | 1 | 377 | 0.27% | 0.05% to 1.49% |
Literature-extracted relations (26)
Shown in this order: chemicals, then diseases.
| Related entity | Kind | Source relation label | Paper | Year |
|---|---|---|---|---|
| Anhydrous glucose | Chemical | associate |
Molecular adaptations of adipose tissue to 6 weeks of morning fasting vs. daily breakfast consumption in lean and obese adults. | 2018 |
| Lycopene | Chemical | negative_correlate |
MicroRNA-let-7f-1 is induced by lycopene and inhibits cell proliferation and triggers apoptosis in prostate cancer. | 2016 |
| Testosterone | Chemical | positive_correlate |
Insulin Resistance and Inflammation in Hypogonadotropic Hypogonadism and Their Reduction After Testosterone Replacement in Men With Type 2 Diabetes. | 2016 |
| EVEROLIMUS | Chemical | negative_correlate |
Systemic and CNS activity of the RET inhibitor vandetanib combined with the mTOR inhibitor everolimus in KIF5B-RET re-arranged non-small cell lung cancer with brain metastases. | 2015 |
| Cholesterol | Chemical | associate |
Postreceptor insulin resistance contributes to human dyslipidemia and hepatic steatosis. | 2009 |
Showing 5 of 26 relation assertions.
Organizations publishing (238)
Shown in this order: most papers first.
| Organization | Type | Papers | Years |
|---|---|---|---|
| Government of the United States of America | Government | 13 | 2012 to 2023 |
| Memorial Sloan Kettering Cancer Center | Hospital | 9 | 2011 to 2022 |
| University of Copenhagen | Academic | 8 | 2012 to 2018 |
| University of London | Academic | 7 | 2009 to 2023 |
| Mass General Brigham | Hospital | 6 | 2013 to 2023 |
Showing 5 of 238 organizations.
Where AKT2 appears
- biological_process
- cancer or benign tumor
- cardiovascular disease
- disorder of visual system
- endocrine system disease
- gastrointestinal disease
- genetic, familial or congenital disease
- immune system disease
- infectious disease
- injury, poisoning or other complication
- integumentary system disease
- measurement
- musculoskeletal or connective tissue disease
- nervous system disease
- nutritional or metabolic disease
- phenotype
- pregnancy or perinatal disease
- reproductive system or breast disease
- urinary system disease
403 diseases touched.
Not on this page
Checked, with nothing recorded for this biomarker: fda companion diagnostic assertions and fda biomarker qualification projects.